RT Journal Article
SR Electronic
T1 Two-way remote monitoring allows effective and realistic provision of home-NIV to COPD patients with persistent hypercapnia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.08.20227892
DO 10.1101/2020.11.08.20227892
A1 McDowell, Grace
A1 Sumowski, Maksymilian
A1 Toellner, Hannah
A1 Karok, Sophia
A1 O’Dwyer, Ciara
A1 Hornsby, Jamie
A1 Lowe, David
A1 Carlin, Chris
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.08.20227892.abstract
AB Background Outcomes for chronic obstructive pulmonary disease (COPD) patients with persistent hypercapnic respiratory failure are improved by long-term home non-invasive ventilation (NIV). Provision of home-NIV presents clinical and service challenges. The aim of this study was to assess outcomes of home-NIV in hypercapnic COPD patients managed remotely.Methods Retrospective analysis of a dataset of 46 COPD patients with persistent hypercapnic respiratory failure who commenced home-NIV managed by two-way remote monitoring (Lumis, AirView, ResMed) between February 2017 and January 2018. The primary outcome of this study was time to readmission or death at 12 months in patients receiving home-NIV versus a retrospectively identified control cohort of 27 patients with hypercapnic COPD who had not been referred for home-NIV.Results The median time to readmission or death was significantly prolonged in patients who commenced home-NIV (median 160 days, 95% CI 69.38-250.63) versus the control cohort (66 days, 95% CI 21.9-110.1; p<0.01). Average time to hospital readmission was 221 days (95% CI, 47.77-394.23) and 70 days (95% CI, 55.31-84.69; p<0.05), respectively. Median decrease in bicarbonate level of 4.9mmol/L (p<0.0151) and daytime PCO2 2.2kPa (p<0.032) demonstrate efficacy of home-NIV. A median reduction of 14 occupied bed days per annum versus previous year prior to NIV was observed per patient who continued home-NIV throughout the study period (N=32).Conclusion These findings confirm the benefits of home-NIV in clinical practice and support the use of two-way remote monitoring as a feasible solution to managing the delivery of home-NIV for COPD patients with persistent hypercapnia.What is the key question?Do COPD patients with persistent hypercapnia benefit from remotely monitored home-NIV?What is the bottom line?Home-NIV supported with two-way remote monitoring prolonged time to readmission or death within 12 months in patients with hypercapnic COPD.Why read on?This is the first study to show that two-way remote monitoring can be an effective and realistic solution in providing access to home-NIV for COPD patients at the necessary scale. The COVID-19 pandemic has mandated remote-management for respiratory care where feasible. This study demonstrates feasibility, safety and efficacy of a remote-management service model for COPD-NIV and provides playbook for adoption by other clinical teams.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRetrospective observational cohort study.Funding StatementProject was supported by department endowment fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS Greater Glasgow & Clyde Local Privacy and Advisory CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in the manuscript is available in NHS GG&C SafeHaven. Data could be provided with standard approval access request. https://www.nhsggc.org.uk/about-us/professional-support-sites/safe-haven/services/#